Sign in

    Madison Elsaadi • B. Riley Securities

    Madison Elsaadi's questions to Arrowhead Pharmaceuticals Inc (ARWR) leadership

    Madison Elsaadi's questions to Arrowhead Pharmaceuticals Inc (ARWR) leadership • Q3 2025

    Question

    Madison Elsaadi asked if the obesity study's sample size is sufficient for statistical conclusions and what dosing frequency would be considered competitive for a muscle-sparing agent.

    Answer

    Management explained that the Phase 1 study is hypothesis-generating and not powered for statistical conclusions but will inform the design of future studies. They stated that the targeted quarterly to semi-annual dosing frequency is expected to be highly competitive in the market.

    Ask Fintool Equity Research AI

    Madison Elsaadi's questions to Eton Pharmaceuticals Inc (ETON) leadership

    Madison Elsaadi's questions to Eton Pharmaceuticals Inc (ETON) leadership • Q2 2025

    Question

    Madison Elsaadi asked for clarification on which products drove the significant revenue beat in the quarter and which are expected to drive growth in the second half of the year. She also requested more detail on the FDA's feedback regarding the Increlex label expansion, including the rationale for a new trial and the specific regulatory pathway.

    Answer

    CFO James Gruber responded that while product-specific revenue is not disclosed, the outperformance was heavily weighted toward Increlex, with Alkindi and Galzin also contributing to growth. CEO Sean Brynjelsen elaborated on the FDA feedback, explaining the proposed path is an open IND to collect U.S. clinical data on patients in the -2 to -3 standard deviation range, mirroring the European label. He expressed confidence in this approach and expects to gain agreement with the agency in Q4.

    Ask Fintool Equity Research AI